Pre-market most active: ALNEV.PA Neovacs S.A. (EURONEXT) €0.001 17 Mar 2026: high volume

ALNEV.PA stock is trading at €0.001 in the EURONEXT pre-market on 17 Mar 2026 with 24,586,723.00 shares changing hands so far, making it one of the most active names before the open. The heavy volume at a market cap of €477.00 highlights speculative interest in Neovacs S.A. (ALNEV.PA, EURONEXT) ahead of any clinical or corporate update. We use Meyka AI-powered market analysis to connect the trading flow to company fundamentals and short-term technical signals.

ALNEV.PA stock pre-market trading and volume

ALNEV.PA stock opened at €0.001 with a day range €0.0009–€0.0011 and volume of 24,586,723.00, versus an average volume of 14,754,257.00, giving a relative volume of 1.67. This elevated turnover is the main driver of the “most active” tag in pre-market trading. Market participants should watch for official news; current public mentions include brief coverage on Investing.com source and the comparative page listing ENXTPA peers source.

ALNEV.PA stock fundamentals and financials

Neovacs S.A. shows a tiny market cap of €477.00 and 476,625.00 shares outstanding, reflecting an extremely low quoted value rather than economic scale. EPS stands at -221.36, and the company reports no meaningful PE ratio. Book value per share is €103.50 and cash per share is €2.50, while the current ratio is 0.63, signalling limited short-term liquidity. R&D intensity is high at 10.94% of revenue per latest metrics, consistent with a biotech in clinical development.

ALNEV.PA stock technicals and momentum

Technical indicators show ALNEV.PA stock is deeply oversold: RSI 18.11 and ADX 56.66 indicate a strong trend with downward momentum but increased directional conviction. The 50-day average price is roughly €0.003 and the 200-day average is €0.565, underscoring the stock’s collapse from historic levels. High volume and an RSI in single digits often attract short-term traders; monitor order book liquidity and spreads in pre-market.

Meyka AI rates ALNEV.PA stock and analyst context

Meyka AI rates ALNEV.PA with a score out of 100: 62.13 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Note the company-level rating dated 2025-02-28 shows a C- / Strong Sell from an alternate screener, so external ratings diverge. Use this grade as one data point; it is not investment advice.

ALNEV.PA stock catalysts, risks and sector context

Neovacs (ALNEV.PA) is a France-based biotech developing therapeutic vaccines including IFNa Kinoid in Phase IIb for lupus and other early-stage programs; clinical updates are the primary catalysts. The healthcare sector in Europe is softer year-to-date, with the Healthcare sector performance showing recent weakness, increasing sector risk for small biotech names. Key risks include cash runway, low liquidity, regulatory outcomes and binary clinical readouts.

ALNEV.PA stock forecast, price target and valuation

Meyka AI’s forecast model projects a near-term monthly level of €0.04 for ALNEV.PA stock, compared with the current €0.001, implying an upside of 3,900.00%; forecasts are model-based projections and not guarantees. Given the illiquid market and absence of consensus price targets, a conservative scenario-based price target range is €0.01–€0.05, reflecting potential clinical progress or micro-cap revaluation, while a downside scenario remains total capital loss due to operational or delisting risk.

Final Thoughts

ALNEV.PA stock trades at €0.001 in the EURONEXT pre-market on 17 Mar 2026 with heavy volume of 24,586,723.00 shares, making it one of the most active small-cap biotech names before the open. Fundamentals show negative EPS -221.36 and constrained liquidity (current ratio 0.63), while technicals (RSI 18.11, ADX 56.66) point to an oversold, high-volatility setup. Meyka AI’s forecast model projects €0.04 monthly, implying 3,900.00% upside versus current price, but this is a model projection and not a guarantee. For traders, the stock’s pre-market activity can present short-term trading opportunities, but long-term investors should weigh clinical binary risk, cash runway, and very low market liquidity. For more on live flows and updates see our ALNEV.PA page on Meyka AI: https://meyka.ai/stocks/ALNEV.PA

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.